Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: A GICOR phase I trial

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 1005-1009

  Arias de la vega, F ^a   Contreras, J ^b   de las heras, M ^c   de la torre, A ^d   Arrazubi, V ^a   Herruzo, I ^b   Prieto, I ^e   Garcia Saenz J A ^c   Romero, J ^d   Calvo, F A ^e  

^a Universidad Pública de Navarra   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Chemoradiation; Erlotinib; Phase I; SCCHN

Indexed keywords

CISPLATIN; ERLOTINIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; FOLLICULITIS; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HUMAN; LARYNX CARCINOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MOUTH CARCINOMA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RASH; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUINAZOLINES;

EID: 84859498036     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr315     Document Type: Article

References (22)

1. Forastiere AA. Is there a new role for induction chemotherapy in the treatment of head and neck cancer? J Natl Cancer Inst 2004; 96: 1647-1649.
2. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
3. Forastiere AA, Trotti A, Pfister DG, Grandis JR. Head and neck cancer: recent advances and new standards of care. J Clin Oncol 2006; 24: 2603-2605.
4. Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008; 83: 489-501.
5. Pfister DG, Laurie SA, Weinstein GS et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006; 24: 3693-3704.
6. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
7. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2659-2665.
8. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
9. Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol 2008; 35: 274-285.
10. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
11. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
12. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
13. Cohen EE, Kane MA, List MA et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 8418-8424.
14. Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
15. Siu LL, Soulieres D, Chen EX et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007; 25: 2178-2183.
16. Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
17. Calvo E, Malik SN, Siu LL et al. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Ann Oncol 2007; 18: 761-767.
18. Agulnik M, da Cunha Santos G, Hedley D et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007; 25: 2184-2190.
19. Wirth LJ, Tishler RB, Haddad RI et al. Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): early results. J Clin Oncol 2007; 25: 6083.
20. Rueda A, Mesía R, Galiana R et al. Gefitinib plus concomitant boost accelerated radiation (AFX-CB) and concurrent weekly cisplatin for locally advanced unresectable squamous cell head and neck carcinomas (SCCHN): a phase II study. J Clin Oncol 2007; 25: 6031.
21. Morris CA, Allen C, Citrin D et al. Pilot phase I study of gefitinib (GEF) in combination with paclitaxel (PAC) and radiation therapy (RT) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) and effects on epidermal growth factor receptor (EGFR) signaling pathway. J Clin Oncol 2007; 25: 16526.
22. Merlano GN, Russi EG, Benasso M et al. Cetuximab (C-mab) and chemoradiation (CTRT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): a phase II study. J Clin Oncol 2007; 25: 6043.